BioCryst de­buts print mag­a­zine for hered­i­tary an­gioede­ma pa­tients tak­ing Or­ladeyo

BioCryst Phar­ma­ceu­ti­cals is go­ing old school with a print mag­a­zine sent in the mail for peo­ple tak­ing its hered­i­tary an­gioede­ma (HAE) drug, Or­ladeyo. In its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER